跳到正文
GMP干货· 心作流云·· 5 天前AI 评分74

FDA在2026年PDA/FDA联合监管大会用检查观察说明设施设计对无菌保障的作用

2026年PDA/FDA 联合监管大会:安全的无菌生产始于设施设计

AI 导读

FDA药品评价与研究中心生产质量办公室的Jason Chancey在2026年PDA/FDA联合监管大会上,以近期检查观察说明仅靠现代化设备并不能保证无菌保障。

正文

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

在2026年PDA/FDA联合监管大会上,FDA明确指出,仅有现代化设备并不能保证无菌保障。本文探讨了FDA检查中发现的GMP缺陷,以及设施设计在无菌生产中的作用。

Modern barrier systems and automation can substantially reduce contamination risks in aseptic processing. However, they only provide effective protection when facility design, maintenance and aseptic behaviour are properly aligned. Jason Chancey, Consumer Safety Officer in the Office of Manufacturing Quality at the FDA Center for Drug Evaluation and Research (CDER), illustrated this point at the 2026 PDA/FDA Joint Regulatory Conference using recent inspection observations.

现代化的隔离系统和自动化技术可以大幅降低无菌生产过程中的污染风险。然而,只有当设施设计、维护和无菌操作行为得到恰当配合时,它们才能提供有效的保护。FDA药品评价与研究中心(CDER)生产质量办公室的消费品安全官Jason Chancey在2026年PDA/FDA联合监管大会上用近期的检查观察结果说明了这一点。

Examples observed by FDA included tape and difficult-to-clean foam cuffs inside barrier systems, an isolator door gasket repaired with tape, non-functional differential pressure gauges and improperly positioned or discoloured silicone bellows. These findings in critical areas demonstrate that equipment originally designed to provide appropriate protection may lose its effectiveness if damage, unsuitable repairs or maintenance deficiencies are not detected and corrected promptly.

FDA观察到的例子包括:隔离系统内部使用胶带和难以清洁的泡沫套袖、隔离器门密封垫用胶带修补、差压表失灵,以及硅胶波纹管安装位置不当或变色。这些在关键区域的发现表明:如果设备损坏、不当维修或维护缺陷未能被及时发现和纠正,原本设计用于提供适当保护的设备也可能失去其有效性。

Figure 1 | Tape and foam cuffs inside an isolator (Source: Jason Chancey, CDER, PDA/FDA Joint Regulatory Conference 2026)
图1 | 隔离器内的胶带和泡沫套袖(来源:Jason Chancey,CDER,PDA/FDA联合监管大会 2026)

Equipment and line design can also influence operator behaviour. Jason Chancey presented an example in which poor access to an intervention point led operators to perform high-risk manual interventions over partially stoppered vials. The issue was not limited to the operator's actions: The position of the line made the intended access route difficult to use. Personnel and material flows, as well as access to foreseeable intervention points, should therefore be considered before equipment is installed. Retrofitted "mini-doors" in barrier systems may make an intervention less difficult, but they do not eliminate the associated contamination risk.

设备和生产线的设计也会影响操作人员的行为。Jason Chancey举了一个例子:由于干预点的可达性差,操作人员被迫在半加塞的西林瓶上方进行高风险的人工干预。问题并不局限于操作人员的操作行为本身——生产线的布局使预期的通行路径难以使用。因此,在安装设备之前,就应当考虑人员和物料的流向,以及对可预见的干预点的可达性。事后在隔离系统中加装的"小门"也许能使干预操作变得不那么困难,但并不能消除与之相关的污染风险。

Figure 2 | High risk manual intervention (Source: Jason Chancey, CDER, PDA/FDA Joint Regulatory Conference 2026)

图2 | 高风险人工干预(来源:Jason Chancey,CDER,PDA/FDA联合监管大会 2026)

Caution is also required when using modular or "drop-in" cleanrooms. Such systems are not inherently unsuitable, but their acceptability depends on their design, airflow, surfaces and state of maintenance. Damaged ceiling panels, insufficient HEPA coverage or airflow directed from the operator back into the critical area may undermine the intended cleanroom performance.

在使用模块化或"即插即用"式洁净室时也需要谨慎。这类系统本身并非不适用,但其可接受性取决于其设计、气流、表面状况和维护状态。天花板面板受损、HEPA覆盖不足,或气流从操作人员一侧回流至关键区域,都可能破坏洁净室预期的性能。

Common Weaknesses in Airflow Visualisation Studies

气流可视化研究的常见缺陷

Issues observed by FDA include:

  • tracer media with unsuitable buoyancy, density or dissipation characteristics,

  • excessive tracer-media velocity,

  • tracer media positioned away from the intervention being evaluated,

  • equipment or interventions that do not represent commercial conditions, and

  • airflow disturbances, vortices or short circuits that are not recognised and assessed.

FDA 观察到的问题包括:

  • 示踪介质的浮力、密度或消散特性不合适;

  • 示踪介质速度过高;

  • 示踪介质的位置远离所评估的干预操作;

  • 设备或干预操作不代表商业化生产条件;

  • 气流扰动、涡流或气流短路未被识别和评估。

Airflow visualisation studies should represent actual operating conditions and include realistic interventions. Any visible airflow irregularity should be acknowledged and evaluated, even if it does not necessarily present a critical risk.

气流可视化研究应反映实际操作条件,并包含真实合理的干预操作。任何可见的气流异常都应被识别和评估,即使它不一定构成关键风险。

Jason Chancey also cautioned against dismissing positive biological indicators following decontamination or sterilisation as "rogue indicators". Such results require a complete investigation, potentially involving material, equipment and service suppliers. Repeating a test until an acceptable result is obtained is not a substitute for root-cause investigation and scientific evaluation.

Jason Chancey还警告说,不应将消毒或灭菌后出现的阳性生物指示剂视为"偶发指示剂"而不予理会。此类结果需要开展完整的调查,调查可能涉及物料、设备和服务供应商。反复重复检测直到获得可接受的结果,并不能替代根本原因调查和科学评估。

Conclusion 结论

The central message was that modern facility technology alone does not ensure sterility assurance. Barrier systems must be appropriately designed, continuously monitored and properly maintained. At the same time, interventions, airflow patterns and human behaviour must be considered realistically from the earliest stages of facility and line design.

核心信息是:仅靠现代化的设施技术并不能保证无菌保障。隔离系统必须设计得当、持续监测并妥善维护。同时,必须从设施和生产线设计的最初阶段就切合实际地考虑干预操作、气流模式和人员行为。

原文来自GMP-Verlag Peither AG网站,点击“阅读原文”可查看原文。

来源:GMP干货 · mp.weixin.qq.com

所属事件

查看事件全部
FDA会议举例:先进隔离设备不等于无菌保障